Ausgabe 6/2022
Inhalt (23 Artikel)
Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFR
Li-Kuei Chen, Chien-Hung Shih, Shiou-Sheng Chen, Zi-Xuan Huang, Yu-Jung Chang, Linyi Chen, Tsung-Hsien Chuang, Kuen-Bao Chen
Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine
Haiqin Ping, Wenjun Yu, Xiaoming Gong, Xin Tong, Cheyu Lin, Zhaojun Chen, Caiyun Cai, Kai Guo, Hengning Ke
Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer
Imene Ben Toumia, Marco Ponassi, Paola Barboro, Erika Iervasi, Gabriela Coronel Vargas, Barbara Banelli, Stefano Fiordoro, Leila Chekir Ghedira, Franz Heinrich Kohnke, Alberto Izzotti, Camillo Rosano
Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations
Jiajia Yuan, Junzhe Song, Chao Chen, Xue Lv, Jie Bai, Jing Yang, Yuan Zhou
Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics
Zhitao Ni, Shaolin Xu, Zheng Yu, Zhongjiang Ye, Rongqi Li, Chuang Chen, Jianhui Yang, Huamin Liu, Ziye Zhou, Xiuhua Zhang
Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα
Zhiwei Chen, Xing Xia, Heyan Chen, Huirong Huang, Xingsi An, Meng Sun, Qing Yao, Kwonseop Kim, Hailin Zhang, Maoping Chu, Ruijie Chen, Yangzom D. Bhutia, Vadivel Ganapathy, Longfa Kou
Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia
Yanfeng Liu, Yan Jia, Yi Liu, Xuefeng Chen, Mei Zhang
TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells’ killing
Xuejia Feng, Gui Yang, Litian Zhang, Shishi Tao, Joong Sup SHIM, Liang Chen, Qingxia Wu
Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer
Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yuji Okuda, Natsuki Fukuda, Mariko Asano, Masahide Takeda, Katsutoshi Nakayama, Masatomo Miura
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
Emiliano Calvo, Cristiana Sessa, Guilherme Harada, Maria de Miguel, Carmen Kahatt, Xarles Erik Luepke-Estefan, Mariano Siguero, Carlos Fernandez-Teruel, Martin Cullell-Young, Anastasios Stathis, Alexander Drilon
Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects
Linlin Hu, Mingmin Cai, Wei Qian, Ting Dou, Qiuyue Sun, Lu Tang, Huiping Wang
Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study
Peng Shen, Bo Qiao, Nenghao Jin, Shuyan Wang
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
Nobuharu Tamaki, Toshifumi Tada, Masayuki Kurosaki, Yutaka Yasui, Hironori Ochi, Toshie Mashiba, Azusa Sakamoto, Hiroyuki Marusawa, Ryoichi Narita, Yasushi Uchida, Takehiro Akahane, Masahiko Kondo, Nami Mori, Shintaro Takaki, Keiji Tsuji, Haruhiko Kobashi, Atsunori Kusakabe, Koichiro Furuta, Hirotaka Arai, Michiko Nonogi, Chikara Ogawa, Takashi Sato, Takashi Tamada, Shinichiro Nakamura, Chitomi Hasebe, Kaoru Tsuchiya, Namiki Izumi
Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer
Toshiyuki Sumi, Yuta Koshshino, Motoki Sekikawa, Yuta Nagahisa, Keigo Matsuura, Naoki Shijubou, Koki Kamada, Hiroki Watanabe, Haruhiko Michimata, Daiki Nagayama, Yusuke Tanaka, Yuichi Yamada, Hirofumi Chiba
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161
Lakshmi Rajdev, Ju-Whei Lee, Steven K. Libutti, Al B. Benson, George A. Fisher Jr, Pamela L. Kunz, Andrew E. Hendifar, Paul Catalano, Peter J. O’Dwyer
Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer
Toshiyuki Sumi, Motoki Sekikawa, Yuta Nagahisa, Keigo Matsuura, Naoki Shijubou, Koki Kamada, Hiroki Watanabe, Yuichi Yamada, Yusuke Tanaka, Hirofumi Chiba
BMP2 as a promising anticancer approach: functions and molecular mechanisms
Tong-tong Li, Yong-wei Lai, Xu Han, Xin Niu, Peng-xia Zhang
CD25-targeted antibody–drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma
Bo Xu, Shaoqian Li, Bo Kang, Shangzhi Fan, Zunbo He, Jiecan Zhou
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy
Shinsuke Ogusu, Ryo Ariyasu, Takahiro Akita, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report
Chunguang Wang, Shu Chen, Qianru He, Tingting Sun, Peiran Xu
Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutations
Shinichiro Okauchi, Hiroaki Satoh
Correction to: Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine
Haiqin Ping, Wenjun Yu, Xiaoming Gong, Xin Tong, Cheyu Lin, Zhaojun Chen, Caiyun Cai, Kai Guo, Hengning Ke
Correction to: A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: A case report
Chunguang Wang, Shu Chen, Qianru He, Tingting Sun, Peiran Xu